AŞIRI AKTİF MESANE SENDROMU OLAN KADINLARDA TROSPIUM CHLORIDE TEDAVİSİNİN ETKİNLİĞİ

Abstract

Amaç: Aşırı aktif mesane sendromu bulunan kadınlarda trospium tedavisinin etkinliği ve bu etkinin ürodinamik bulgular ile ilişkisi araştırıldı. Yöntem: Aşırı aktif mesane sendromu bulunan 44 kadın hasta çalışmaya alındı. 8 haftalık trospiyum tedavisinden sonra, hastaların tedavi öncesi ve sonrası OAB-V8 semptom skoru, ürodinamik bulguları karşılaştırıldı. Bulgular: Ortalama OAB-V8 semptom skoru tedavi ile birlikte anlamlı olarak düşük bulundu (11.9±6.3; 24.9±5.1; p<0.05).Detrusor aşırı aktivitesi bulunan kadın hastaların (10.3±4.1) detrusor aşırı aktivitesi olmayan kadın hastalara (14.2+5.3) göre trospium tedavisinden daha fazla fayda gördükleri saptandı. Sonuç: Trospium tedavisi ispatlanmış detrusor aşırı aktivitesi olan kadın hastalarda daha etkili bulunmuştur. Anahtar Kelimeler: Aşırı aktif mesane, İşeme disfonksiyonu, Farmakoterapi

Keywords

• -

References

1. Abrams P, Cardozo L, Fall M, et al. The standardization
2. of terminology of lower urinary tract function: report
3. from the Standardization Subcommittee of the
4. International Continence Society. Neurourol Urodyn
5. : 21: 167-178.
6. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J,
7. Wein AJ. How widespread are the symptoms of an
8. overactive bladder and how are they managed? A

9. population based prevalence study. BJU Int 2001: 87:
10. -766.
11. Milson I, Stewart W, Thuroff J. The prevalence of
12. overactive bladder. Am J Manag Care 6 (Suppl. 11)
13. : S565-5573
14. Yoshimura N, de Groat WC. Neural control of lower
15. urinary tract. Int J Urol 1997: 4: 111-125.
16. De Groat WC. A neurologic basis for the overactive
17. bladder. Urology suppl. 1997: 50: 36-52.
18. Wang P, Luthin GR, Ruggieri MR. Muscarinic
19. acetylcholine receptor subtypes mediating urinary
20. bladder contractility and coupling to GTP binding
21. proteins. J Pharmacol Exp Ther 1995: 273: 959-966.
22. Yoshimura N, Chancellor MB. Current and future
23. pharmacological treatment for overactive bladder. J Urol
24. : 168:1897-1913.
25. Wein AJ. Neuromuscular dysfunction of lower urinary
26. tract and its management. In: Walsh PC, Retik AB,
27. Darracot Vaughan jr. E, Wein AJ (eds) Campell’s
28. Urology. Saunders, Philadelphia, 2002: 931-1026.
29. Madersbacher H, Rovner E. Trospium chloride: the
30. European experience. Expert Opin Pharmacother 2006:
31. :1373-1380.
32. Hofner K, Oelke M, Machtens S, Grunewald T.
33. Trospium chloride an effective drug in the treatment of
34. overactive bladder and detrusor hyperreflexia. World J
35. Urol 2001: 19: 336-343.
36. Guay DR. Clinical pharmacokinetics of drugs used to
37. treat urge incontinence. Clin Pharmacokinet 1986: 42:
38. -1285.
39. Vereecken RL. A critical view on the value of
40. urodynamics in non neurogenic incontinence in women.
41. Int Urogynecol J 2000: 11: 188-195.
42. Coyne KS, Zyczynski T, Margolis MK, Elinof V,
43. Roberts RG. Validation of an overactive bladder
44. awareness tool for use in primary care settings. Adv
45. Ther 2005: 22: 381-394.
46. Hu TW, Wagner TH, Bentkover JD, et al. Estimated
47. economic cost of overactive bladder in the United
48. States. Urology 2003: 61: 1123-1128.
49. Abrams P, Anderson KE. Muscarinic receptor
50. anragonists for overactive bladder. BTU Int 2007: 100:
51. -1006.
52. Zinner M, Gittelman M, Haris R, et al. Trospium
53. chloride improves bladder symptoms. A multicenter
54. phase III trial. J Urol 2004:171: 2311-2315.
55. Rudy D, Cline K, Harris R, et al.Multicenter phase III
56. trial studying trospium chloride in patients with over
57. active bladder. Urology 2006; 67:275-280.
58. Halaska M, Ralph G, Wiedeman A, et al. Controlled,
59. double-blind, multicenter clinical trial to investigate
60. long-term tolerability and efficacy of trospium chloride
61. in patients with detrusor instability. World J Urol 2002:
62. : 392-399.
63. Flisser A, Walmsey K, Blavias JG. Urodynamics
64. classification of patients with symptoms of overactive
65. bladder. J Urol 2003: 169: 529-533.
66. Lin LY, Yeh NH, Lin CY, Sheu BC, Lin HH.
67. Comparisons of urodynamic characteristics between
68. female patients with overactive bladder and overactive
69. bladder plus stress urinary incontinence. Urology 2004:
70. : 945-949.
71. Digesu GA, Khullar V, Cardozo L, Stefano S.
72. Overactive bladder symptoms: Do we need
73. urodynamics? Neurourol Urodyn 2003: 22: 105-108.
74. Ouslander JG. Management of overactive bladder. N
75. Engl J Med 2004: 350: 786-799.
76. Staskin DR, Wein AJ, Andersson KE, et al. Overview
77. consensus statement. Urology 2003: 61: 1128-8.
78. Alloussi S, Laval KU, Eckert R, et al. Trospium chloride
79. in patients with motor urge symptoms: A double blind,
80. randomised, multicentre, placebo controlled study. J
81. Drug Asses 1999: 2: 27-39.